{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:48:03Z","timestamp":1788994083857,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00228-025-03934-3","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T05:14:18Z","timestamp":1768626858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of CGRP monoclonal antibodies for migraine prevention in episodic migraine; a network Meta-analysis"],"prefix":"10.1007","volume":"82","author":[{"given":"Ishwa","family":"Shakir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faizan","family":"Shahzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahsan","family":"Shabbir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Shahabuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroon","family":"Shabbir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobia","family":"Karamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Hulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rauf","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Ijlal","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"key":"3934_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-016-0542-3","volume":"14","author":"S Mannix","year":"2016","unstructured":"Mannix S, Skalicky A, Buse DC, Desai P, Sapra S, Ortmeier B, Widnell K, Hareendran A (2016) Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches. Health Qual Life Outcomes 14:1\u20131","journal-title":"Health Qual Life Outcomes"},{"key":"3934_CR2","doi-asserted-by":"crossref","unstructured":"Buse DC, Rupnow MF, Lipton RB Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. InMayo Clinic Proceedings 2009 May 1 (Vol. 84, No. 5, pp. 422\u2013435). Elsevier","DOI":"10.4065\/84.5.422"},{"issue":"1","key":"3934_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jval.2012.08.2212","volume":"16","author":"D Serrano","year":"2013","unstructured":"Serrano D, Manack AN, Reed ML, Buse DC, Varon SF, Lipton RB (2013) Cost and predictors of lost productive time in chronic migraine and episodic migraine: results from the American migraine prevalence and prevention (AMPP) study. Value Health 16(1):31\u201338","journal-title":"Value Health"},{"key":"3934_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10072-015-2130-4","volume":"36","author":"D D\u2019amico","year":"2015","unstructured":"D\u2019amico D, Grazzi L, Curone M, Di Fiore P, Proietti Cecchini A, Leonardi M, Scaratti C, Raggi A (2015) Difficulties in work activities and the pervasive effect over disability in patients with episodic and chronic migraine. Neurol Sci 36:9\u201311","journal-title":"Neurol Sci"},{"issue":"2","key":"3934_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41582-022-00763-1","volume":"19","author":"TJ Steiner","year":"2023","unstructured":"Steiner TJ, Stovner LJ (2023) Global epidemiology of migraine and its implications for public health and health policy. Nat Rev Neurol 19(2):109\u2013117","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"3934_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68(5):343\u2013349","journal-title":"Neurology"},{"issue":"8","key":"3934_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, Pozo-Rosich P, Martelletti P, Ducros A, Lant\u00e9ri-Minet M, Braschinsky M (2021) Diagnosis and management of migraine in ten steps. Nat Rev Neurol 17(8):501\u2013514","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"3934_CR8","first-page":"17","volume":"99","author":"H Ha","year":"2019","unstructured":"Ha H, Gonzalez A (2019) Migraine headache prophylaxis. Am Fam Physician 99(1):17\u201324","journal-title":"Am Fam Physician"},{"issue":"1","key":"3934_CR9","first-page":"22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 20(1):22\u201333","journal-title":"J Manag Care Pharm"},{"issue":"8","key":"3934_CR10","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/j.1526-4610.2011.01985.x","volume":"51","author":"P Rizzoli","year":"2011","unstructured":"Rizzoli P, Loder EW (2011) Tolerance to the beneficial effects of prophylactic migraine drugs: a systematic review of causes and mechanisms. Headache 51(8):1323\u20131335","journal-title":"Headache"},{"issue":"3","key":"3934_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.pharmthera.2009.09.003","volume":"124","author":"CM Villal\u00f3n","year":"2009","unstructured":"Villal\u00f3n CM, Olesen J (2009) The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther 124(3):309\u2013323","journal-title":"Pharmacol Ther"},{"issue":"1","key":"3934_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.410330109","volume":"33","author":"PJ Goadsby","year":"1993","unstructured":"Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Annals Neurology: Official J Am Neurol Association Child Neurol Soc 33(1):48\u201356","journal-title":"Annals Neurology: Official J Am Neurol Association Child Neurol Soc"},{"issue":"2","key":"3934_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.410280213","volume":"28","author":"PJ Goadsby","year":"1990","unstructured":"Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Annals Neurology: Official J Am Neurol Association Child Neurol Soc 28(2):183\u2013187","journal-title":"Annals Neurology: Official J Am Neurol Association Child Neurol Soc"},{"key":"3934_CR14","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40263-021-00834-9","volume":"35","author":"LH Overeem","year":"2021","unstructured":"Overeem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U (2021) Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta-analysis. CNS Drugs 35:805\u2013820","journal-title":"CNS Drugs"},{"issue":"7","key":"3934_CR15","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1177\/0333102421989601","volume":"41","author":"K Drellia","year":"2021","unstructured":"Drellia K, Kokoti L, Deligianni CI, Papadopoulos D, Mitsikostas DD (2021) Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis. Cephalalgia 41(7):851\u2013864","journal-title":"Cephalalgia"},{"issue":"10","key":"3934_CR16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrneurol.2010.127","volume":"6","author":"TW Ho","year":"2010","unstructured":"Ho TW, Edvinsson L, Goadsby PJ (2010) CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 6(10):573\u2013582","journal-title":"Nat Rev Neurol"},{"key":"3934_CR17","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","DOI":"10.1136\/bmj.n71"},{"key":"3934_CR18","doi-asserted-by":"crossref","unstructured":"Higgins JP (2011) The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. The Cochrane Collaboration","DOI":"10.1136\/bmj.d5928"},{"issue":"19","key":"3934_CR19","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999\u20132008","journal-title":"JAMA"},{"issue":"8","key":"3934_CR20","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia 38(8):1442\u20131454","journal-title":"Cephalalgia"},{"issue":"7","key":"3934_CR21","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/head.14178","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, Tatsuoka Y, Imai N, Ning X, Ishida M, Nagano K, Iba K, Kondo H, Koga N (2021) Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo\u2010controlled, parallel\u2010group trial in Japanese and Korean patients. Headache J Head Face Pain 61(7):1102\u20131111","journal-title":"Headache J Head Face Pain"},{"issue":"6","key":"3934_CR22","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38(6):1026\u20131037","journal-title":"Cephalalgia"},{"issue":"13","key":"3934_CR23","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1177\/03331024211024160","volume":"41","author":"SJ Wang","year":"2021","unstructured":"Wang SJ, Roxas Jr AA, Saravia B, Kim BK, Chowdhury D, Riachi N, Tai ML, Tanprawate S, Ngoc TT, Zhao YJ, Mikol DD (2021) Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: the EMPOwER study. Cephalalgia 41(13):1285\u201397","journal-title":"Cephalalgia"},{"issue":"2","key":"3934_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jamaneurol.2017.3859","volume":"75","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Oakes TM, Zhang QI, Ferguson MB, Martinez J, Camporeale A, Johnson KW, Shan Q, Carter J, Schacht A, Goadsby PJ (2018) Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol 75(2):187\u2013193","journal-title":"JAMA Neurol"},{"issue":"9","key":"3934_CR25","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75(9):1080\u20131088","journal-title":"JAMA Neurol"},{"issue":"10","key":"3934_CR26","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1111\/head.13652","volume":"59","author":"F Sakai","year":"2019","unstructured":"Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Lenz R, Wang Y, Cheng S, Hirama T, Mikol DD (2019) A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults. Headache J Head Face Pain 59(10):1731\u20131742","journal-title":"Headache J Head Face Pain"},{"key":"3934_CR27","doi-asserted-by":"publisher","first-page":"251581632093257","DOI":"10.1177\/2515816320932573","volume":"3","author":"F Sakai","year":"2020","unstructured":"Sakai F, Ozeki A, Skljarevski V (2020) Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: a phase 2 randomized controlled clinical trial. Cephalalgia Rep 3:2515816320932573","journal-title":"Cephalalgia Rep"},{"issue":"3","key":"3934_CR28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4103\/aian.aian_199_22","volume":"25","author":"D Chowdhury","year":"2022","unstructured":"Chowdhury D, Chaudhuri JR, Ghosh P, Kulkarni R, Singh S, Thakur S, Thorat AV (2022) Efficacy and tolerability of erenumab for prevention of episodic migraine in India. Ann Indian Acad Neurol 25(3):433\u2013440","journal-title":"Ann Indian Acad Neurol"},{"issue":"3","key":"3934_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Smith J (2020) Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40(3):241\u2013254","journal-title":"Cephalalgia"},{"issue":"11","key":"3934_CR30","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1474-4422(15)00249-5","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14(11):1081\u20131090","journal-title":"Lancet Neurol"},{"issue":"1","key":"3934_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s10194-022-01458-0","volume":"23","author":"B Hu","year":"2022","unstructured":"Hu B, Li G, Li X, Wu S, Yu T, Li X, Zhao H, Jia Z, Zhuang J, Yu S (2022) Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study. J Headache Pain 23(1):90","journal-title":"J Headache Pain"},{"issue":"22","key":"3934_CR32","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377(22):2123\u20132132","journal-title":"N Engl J Med"},{"issue":"10161","key":"3934_CR33","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392(10161):2280\u20132287","journal-title":"Lancet"},{"issue":"4","key":"3934_CR34","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(16)00019-3","volume":"15","author":"H Sun","year":"2016","unstructured":"Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Lenz R (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15(4):382\u2013390","journal-title":"Lancet Neurol"},{"issue":"1","key":"3934_CR35","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/0333102419877663","volume":"40","author":"P Tfelt-Hansen","year":"2020","unstructured":"Tfelt-Hansen P, Diener HC, Steiner TJ (2020) Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: a mini-review. Cephalalgia 40(1):122\u2013126","journal-title":"Cephalalgia"},{"key":"3934_CR36","doi-asserted-by":"publisher","unstructured":"Shibata M, Nakamura T, Ozeki A, Ueda K, Nichols RM (2020) Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: Japan Phase 2 Study. J Pain Res 13:3531\u20133538. https:\/\/doi.org\/10.2147\/JPR.S287781.","DOI":"10.2147\/JPR.S287781"},{"issue":"4","key":"3934_CR37","doi-asserted-by":"publisher","first-page":"033310242311593","DOI":"10.1177\/03331024231159366","volume":"43","author":"F Haghdoost","year":"2023","unstructured":"Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P (2023) Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia 43(4):03331024231159366","journal-title":"Cephalalgia"},{"key":"3934_CR38","doi-asserted-by":"publisher","unstructured":"Ray JC, Dalic L, Baker J, Cheng S, Hutton EJ, Matharu M (2024) Twelve-month efficacy of CGRP monoclonal antibodies and predictive value of short-term response: results of an Australian multicentre study. BMJ Neurol Open 6(1):e000547.\u00a0https:\/\/doi.org\/10.1136\/bmjno-2023-000547","DOI":"10.1136\/bmjno-2023-000547"},{"issue":"1","key":"3934_CR39","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s10194-023-01561-w","volume":"24","author":"P Barbanti","year":"2023","unstructured":"Barbanti P, Egeo G, Aurilia C, Torelli P, Finocchi C, d\u2019Onofrio F, d\u2019Onofrio L, Rao R, Messina S, Di Clemente L, Ranieri A (2023) Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study. J Headache Pain 24(1):30","journal-title":"J Headache Pain"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03934-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03934-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03934-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:03:53Z","timestamp":1771859033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03934-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3934"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03934-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7517901\/v1","asserted-by":"object"}]},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since this is a review article, ethical approval is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study is a systematic review and meta-analysis. It does not involve any new studies with human participants or animals conducted by the authors. Therefore, human ethics approval and consent to participate are not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors would like to declare no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Since this is a review article of already published data, informed consent is waived.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This study is a systematic review and meta-analysis and does not include any new data collected from human participants. All data analyzed were obtained from previously published studies in which informed consent had already been obtained by the original investigators. Therefore, additional consent to participate is not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"27"}}